These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27450645)

  • 1. Fibroblast growth factor 23 and soluble Klotho in patients with autosomal dominant polycystic kidney disease.
    Akiyama K; Mochizuki T; Kataoka H; Tsuchiya K; Nitta K
    Nephrology (Carlton); 2017 Nov; 22(11):848-853. PubMed ID: 27450645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble klotho and autosomal dominant polycystic kidney disease.
    Pavik I; Jaeger P; Ebner L; Poster D; Krauer F; Kistler AD; Rentsch K; Andreisek G; Wagner CA; Devuyst O; Wüthrich RP; Schmid C; Serra AL
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):248-57. PubMed ID: 22193235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate.
    Pavik I; Jaeger P; Kistler AD; Poster D; Krauer F; Cavelti-Weder C; Rentsch KM; Wüthrich RP; Serra AL
    Kidney Int; 2011 Jan; 79(2):234-40. PubMed ID: 20944552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High serum soluble α-Klotho levels in patients with autosomal dominant polycystic kidney disease.
    Sari F; Inci A; Dolu S; Ellidag HY; Cetinkaya R; Ersoy FF
    J Investig Med; 2017 Feb; 65(2):358-362. PubMed ID: 27733443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A decreased soluble Klotho level with normal eGFR, FGF23, serum phosphate, and FEP in an ADPKD patient with enlarged kidneys due to multiple cysts.
    Kanai T; Shiizaki K; Betsui H; Aoyagi J; Yamagata T
    CEN Case Rep; 2018 Nov; 7(2):259-263. PubMed ID: 29767399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
    Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
    Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic Production of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease.
    Bienaimé F; Ambolet A; Aussilhou B; Brazier F; Fouchard M; Viau A; Barre P; Tissier AM; Correas JM; Paradis V; Terzi F; Friedlander G; Knebelmann B; Joly D; Prié D
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2319-2328. PubMed ID: 29618028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Association of Fibroblast Growth Factor 23 with Arterial Stiffness and Atherosclerosis in Patients with Autosomal Dominant Polycystic Kidney Disease.
    Coban M; Inci A; Yılmaz U; Asilturk E
    Kidney Blood Press Res; 2018; 43(4):1160-1173. PubMed ID: 30064143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease.
    Wan M; Smith C; Shah V; Gullet A; Wells D; Rees L; Shroff R
    Nephrol Dial Transplant; 2013 Jan; 28(1):153-61. PubMed ID: 23180879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.
    Liabeuf S; Ryckelynck JP; El Esper N; Ureña P; Combe C; Dussol B; Fouque D; Vanhille P; Frimat L; Thervet E; Mentaverri R; Prié D; Choukroun G;
    Clin J Am Soc Nephrol; 2017 Dec; 12(12):1930-1940. PubMed ID: 29074818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor 23/klotho axis in chronic kidney disease.
    Nitta K; Nagano N; Tsuchiya K
    Nephron Clin Pract; 2014; 128(1-2):1-10. PubMed ID: 25402964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
    Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
    Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis.
    Shimamura Y; Hamada K; Inoue K; Ogata K; Ishihara M; Kagawa T; Inoue M; Fujimoto S; Ikebe M; Yuasa K; Yamanaka S; Sugiura T; Terada Y
    Clin Exp Nephrol; 2012 Oct; 16(5):722-9. PubMed ID: 22457086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
    Chonchol M; Gitomer B; Isakova T; Cai X; Salusky I; Pereira R; Abebe K; Torres V; Steinman TI; Grantham JJ; Chapman AB; Schrier RW; Wolf M
    Clin J Am Soc Nephrol; 2017 Sep; 12(9):1461-1469. PubMed ID: 28705885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between cFGF23/Klotho ratio and phosphate levels in patients with chronic kidney disease.
    Liu Z; Zhou H; Chen X; Chen H; Wang Y; Wang T; Cai L; Hong Y; Ke H; Zheng J
    Int Urol Nephrol; 2019 Mar; 51(3):503-507. PubMed ID: 30689182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum klotho: relation to fibroblast growth factor-23 and other regulators of phosphate metabolism in children with chronic kidney disease.
    Sawires HK; Essam RM; Morgan MF; Mahmoud RA
    Nephron; 2015; 129(4):293-9. PubMed ID: 25766835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M; Komaba H; Fukagawa M
    Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arterial dysfunction in early autosomal dominant polycystic kidney disease independent of fibroblast growth factor 23.
    Yildiz A; Gul CB; Ersoy A; Asiltas B; Ermurat S; Dogan S; Karaagac K; Sag S; Oruc A; Aktas N; Ocakoglu G; Dogan I; Gullulu S; Gullulu M
    Iran J Kidney Dis; 2014 Nov; 8(6):443-9. PubMed ID: 25362218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for Bone and Mineral Metabolism Alterations in Children With Autosomal Dominant Polycystic Kidney Disease.
    De Rechter S; Bacchetta J; Godefroid N; Dubourg L; Cochat P; Maquet J; Raes A; De Schepper J; Vermeersch P; Van Dyck M; Levtchenko E; D'Haese P; Evenepoel P; Mekahli D
    J Clin Endocrinol Metab; 2017 Nov; 102(11):4210-4217. PubMed ID: 29092060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGF23 and Klotho in relation to markers of endothelial dysfunction in kidney transplant recipients.
    Malyszko J; Koc-Zorawska E; Matuszkiewicz-Rowinska J; Malyszko J
    Transplant Proc; 2014 Oct; 46(8):2647-50. PubMed ID: 25380886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.